1853133145
Wysdom Radio™

Advertise on podcast: Wysdom Radio™

Rating
★★★★★
5
from
2 reviews
This podcast has
56 episodes
Language
English
Publisher
Wysdom
Explicit
No
Date created
2025/11/14
Latest episode
2026/11/04
Average duration
19 min.
Release period
7 days

Description

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

Unlock Wysdom Radio™ podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Wysdom Radio™ podcast


Communicating After Complications: The Untaught Procedure
2026/11/04
This episode features a recorded lecture by Dr. Gary Ansel on the "last untaught procedure": communicating with patients and families after a procedural complication, introduced by Dr. Rusty Hofmann. It's the kind of firsthand teaching we're proud to bring to Wysdom. The Premise: Every proceduralist remembers their first catastrophic complication. We rehearse wire crossings and balloon inflations, but almost none of us were taught what to say when we walk into the waiting room afterward.Why It Matters: The US sees 70,000 to 90,000 malpractice claims a year, 25,000 to 40,000 of them related to procedures. Most complications don't become lawsuits because of the complication itself. Many begin because patients believe information was withheld.Complication vs. Error: A complication is a known procedural risk that can occur despite excellent care. A medical error is a preventable deviation from acceptable care, and it should be acknowledged honestly. Either way, don't blame the nurses, the industry rep, the equipment or another physician, and don't declare fault or malpractice, because negligence is a legal conclusion that requires a structured review.The Conversation: Explain what happened, the patient's current condition, what is known and unknown, the immediate plan, and when the family will hear from you again. Lead with empathy, and avoid speculation, blame, defensiveness and jargon.A Case: In a PCI perforation that led to tamponade and a trip to the OR, Dr. Ansel led the family conversation himself, then held a same-day team debrief and reviewed the case for system and training improvements.The Curriculum Gap: Communication-and-resolution programs outperform deny-and-defend, with greater family trust, fewer lawsuits and lower liability costs. Yet post-complication disclosure is rarely standardized or assessed in residency, largely absent from fellowship training, and missing from the major meetings. Dr. Ansel's CLEAR framework offers a structured approach.Tune in to learn why the procedure ends when the sheath comes out, but professionalism begins when you walk into the family waiting room.
Early TIPS in Acute Variceal Bleeding
2026/10/28
This Fundamentals episode breaks down the landmark Early TIPS trial (Garcia-Pagán et al., NEJM 2010) on preemptive covered TIPS for high-risk acute esophageal variceal bleeding. Following, there is an expert commentary by Dr. Michael D. Darcy, retired chief of interventional radiology at Mallinckrodt Institute of Radiology, Washington University in St. Louis. The Premise: Standard care (vasoactive drugs, antibiotics, and banding) fails in 10–15% of patients. Rescue TIPS controls bleeding but often arrives too late, when mortality is already high.The Study: Nine European centers randomized 63 high-risk patients (Child-Pugh C 10–13, or Child-Pugh B 7–9 with active bleeding at endoscopy) within 24 hours of admission to early PTFE-covered TIPS (within 72 hours) versus drugs plus banding with rescue TIPS allowed.Efficacy: The primary composite (failure to control bleeding or clinically significant rebleeding at one year) hit 1 of 32 early-TIPS patients versus 14 of 31 on standard care (P=0.001). One-year freedom from that endpoint was 97% versus 50% (NNT 2.1).Survival: Deaths were 4 versus 12. Six-week survival was 97% versus 67% (NNT 3.3); one-year survival was 86% versus 61% (NNT 4.0).Safety & burden: No technical failures. Hepatic encephalopathy at one year was 28% versus 40% (not statistically significant). ICU days were 3.6 versus 8.6.Caveats: Small open-label trial (63 of 359 screened), highly selected population, one-sided sample-size calculation, baseline imbalance in prior encephalopathy, and educational grant support from Gore.Expert Take: Dr. Darcy puts the paper in context for endovascular practice — why hepatology-led dissemination mattered, why encephalopathy still deserves respect, and why current Viatorr controlled-expansion technique often starts at 6 mm rather than the trial’s 8→10 mm step-up.Tune in to learn when early covered TIPS belongs in the pathway for high-risk variceal bleed. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Garcia-Pagán JC, C**a K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370-2379.
Ablate (RFA) and Stabilize (Cement): OsteoCool RFA for Painful Bone Metastases, with Dr. Jason Levy (OPuS One)
2026/10/21
This masterclass episode breaks down OPuS One, the prospective, multinational study of OsteoCool radiofrequency ablation (RFA) plus cement for painful lytic metastases of the spine and pelvis. Following, there is an expert commentary by Dr. Jason R. Levy of Northside Hospital, Atlanta. The Premise: External beam radiation can take 3 to 6 weeks to relieve bone metastasis pain. OPuS One asked whether ablating the tumor and stabilizing the bone could bring relief faster and keep it.The Study: 206 patients were treated at 15 centers, with lytic or mixed lesions in the thoracolumbar spine, periacetabulum, iliac crest or sacrum. Cement followed RFA in 97% of cases, and technical success was 99%.Efficacy: Worst pain, average pain, pain interference and quality of life improved significantly by day 3, and the improvement was sustained through 12 months.Durability: Complete or partial pain response rose from 53% at day 3 to 74% at 12 months (of n=59), and more patients lowered their opioid dose than raised it at every visit.Safety: Device- or procedure-related adverse events occurred in 6 of 206 patients (2.9%), with no fractures at treated sites.Caveats: OPuS One was a single-arm, industry-funded (Medtronic) study with no comparator and heavy dropout, and the effect of RFA can't be separated from the cement.Expert Take: Dr. Levy explains where ablation and cement fit alongside radiation and systemic therapy in palliative oncology, and what endovascular and image-guided specialists can offer patients with painful bone metastases.Tune in to learn how a single minimally invasive procedure can bring pain relief from bone metastases in days rather than weeks. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609. https://doi.org/10.1007/s00270-023-03417-x
EMMY at 10 Years: Two-Thirds Avoid Hysterectomy
2026/10/14
This fundamentals episode breaks down the 10-year results of the EMMY trial, the Dutch randomized comparison of uterine artery embolization (UAE) versus hysterectomy for symptomatic uterine fibroids, and the longest randomized follow-up of the two treatments reported so far. Following, there is an expert commentary by Dr. James Spies, Chair of Radiology at Georgetown University. The Premise: Since 1995, UAE has been described as an alternative to hysterectomy for symptomatic fibroids. EMMY asked whether the benefit holds up a decade later.The Trial: 28 Dutch hospitals randomized 177 premenopausal women with heavy menstrual bleeding from fibroids, all eligible for hysterectomy, 1:1 between 2002 and 2004. 81 underwent UAE and 75 hysterectomy, with a mean follow-up of 133 months.Efficacy: By 10 years, 28 of 81 UAE patients (35%) had a secondary hysterectomy, 5 of them between years 5 and 10. About two-thirds avoided hysterectomy, and the success rate was 69% after an initially successful UAE.Quality of Life: Generic quality of life improved after treatment in both groups and stayed stable at 10 years with no difference between arms. Urinary and bowel function scores fell in both groups, probably from aging, without significant differences between arms.Satisfaction: 78% of UAE patients and 87% of hysterectomy patients were (very) satisfied (P = .77), and 81% versus 84% would recommend their treatment to a friend.The Catch: Secondary hysterectomies kept accruing beyond 5 years, and UAE failure was associated with BMI above 25 (OR 3.29) and smoking (OR 3.24), so long-term follow-up matters when counseling patients.Expert Take: Dr. Spies calls EMMY one of the landmark studies in uterine embolization, but notes issues that may skew long-term results: 17% of patients did not have both uterine arteries embolized and were counted as procedural failures, partly because many sites were performing their first embolizations, and patient management was handled entirely by gynecologists. As the longest follow-up of a randomized trial, and unlikely to be matched in quality, he says it remains the gold standard for long-term outcomes.Tune in to learn why UAE is a well-documented, less invasive alternative to hysterectomy that eligible patients should be counseled on. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2016.06.051
Beyond the Drug: What Makes TACE Work?
2026/10/07
This episode breaks down PRECISION V, the 2010 randomized trial that helped make drug-eluting beads a standard option for hepatocellular carcinoma (HCC), and tests its conclusions against later bland-bead and anatomy data. Following, there is an expert commentary by Dr. Premal Trivedi, Chief of Interventional Radiology at the University of Colorado. The Premise: Conventional TACE uses an unstable lipiodol emulsion that leaks doxorubicin into the systemic circulation. Drug-eluting beads promised to hold the drug in the tumor and block flow permanently.Efficacy: In about 200 BCLC A/B patients, six-month objective response was 51.6% with DC Bead versus 43.5% with conventional TACE (p = 0.11), so the trial missed its primary endpoint. A post hoc advanced-disease subgroup favored the beads (52.4% versus 34.7%).Toxicity: Bead patients received more doxorubicin but had far less alopecia (1.1% versus 20.4%), lower peak ALT and preserved LVEF. Post-embolization syndrome was nearly identical.The Catch: The MSKCC Brown trial compared doxorubicin-loaded beads with bland beads and found essentially the same response and survival, which suggests ischemia, not the drug, is doing the work.Caveats: The trial was an industry-sponsored phase II study with six months of follow-up and no survival endpoints. It was underpowered once the control arm outperformed expectations.Expert Take: Dr. Trivedi notes that systemic doxorubicin alone yields only about a 10% response in HCC, and that most of TACE's benefit comes from the depth and completeness of ischemia.Tune in to learn why the embolization, not the chemotherapy, may be doing the heavy lifting in TACE. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
Infra-popliteal Bioresorbable Stents: The NEJM LIFE-BTK Trial
2026/09/30
This episode breaks down LIFE-BTK, the 2024 New England Journal of Medicine randomized trial testing whether a drug-eluting resorbable scaffold beats plain balloon angioplasty for infrapopliteal artery disease in chronic limb-threatening ischemia. The Premise: Below the knee has been a graveyard of failed devices. A scaffold that resists recoil, elutes an antiproliferative drug, then dissolves promises structural support without a permanent metal cage.Efficacy: In 261 CLTI patients randomized 2:1, one-year freedom from the primary composite was 74% with the scaffold versus 44% with angioplasty, though the separation was driven largely by binary restenosis (76% versus 50%).Acute Mechanics: Core-lab technical success was 91% versus 70%, with bailout stenting needed in 6% of angioplasty cases and none in the scaffold arm.The Catch: Every major safety event was in the scaffold arm, including two perioperative deaths and four above-ankle amputations, three in limbs with patent scaffolds. Wound healing was numerically lower (45% versus 56%).Durability: As the scaffold resorbs, the benefit holds. At three years the composite endpoint remained higher for the scaffold, 59.5% versus 44.8%.Caveats: Only about 3% of screened patients enrolled, lesions were short and lightly calcified, vessel prep was mandatory only in the scaffold arm, and DAPT ran 12 months versus 1, all favoring the scaffold.Tune in to learn how the first fully resorbable below-the-knee scaffold stacked up against angioplasty, and where the trial's design should temper how you apply it. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Varcoe RL, DeRubertis BG, Kolluri R, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390:9-19. https://doi.org/10.1056/NEJMoa2305637
Fractured IVC Filter Fragments: The Penn Perspective
2026/09/23
This episode features expert commentary from Dr. Scott Trerotola of Penn Medicine, responding to our recent episode on Stanford's fractured IVC filter registry titled, Fractured IVC Filter Fragments: When to Chase the Metal. Shared Ceiling: Both the Penn and Stanford series found that, at best, about half of patients leave with every fragment removed. Some extravascular fragments can still be reached by direct CT- or fluoro-guided puncture.Pulmonary Is Not a Parking Spot: Dr. Trerotola argues that a fragment moving from the heart into the lungs is not a success. Fragments can be coughed up or reach the systemic circulation, and removal is low risk in experienced hands.Radiation in Perspective: Penn's median fluoroscopy time was 27 minutes, so dose should not drive the decision.Tune in to hear why a fragment in the lung is still worth chasing.
The Golden Era of PE Trials: PRAGUE-26
2026/09/16
This episode breaks down PRAGUE-26, a 558-patient NEJM randomized trial from 11 Czech centers testing whether low-dose thrombolysis through cheap generic infusion catheters beats anticoagulation alone, with expert commentary throughout from Dr. Jay Giri of Penn Medicine. The Protocol: Standard 4 French infusion catheters, no ultrasound facilitation, alteplase capped at 20 mg over a mean infusion of 9.3 hours. Median time from randomization to lysis was 76 minutes.The Result: The 7-day composite of death, recurrent PE, or cardiorespiratory decompensation fell from 6.8% to 0.7%, with faster RV recovery and shorter ICU stays.What Drove It: Decompensation, not mortality. The endpoint included a NEWS score of 9 or higher, more sensitive than the vasopressor or arrest criteria used in PEITHO.The Bleeding Tradeoff: Major bleeding was neutral, but two intracranial hemorrhages occurred in the thrombolysis arm versus zero with anticoagulation.The Cost Argument, Examined: Generic catheters are cheaper to buy, but Dr. Giri notes that US reimbursement places EKOS cases in a different DRG that covers the catheter. This was also not a head-to-head test of ultrasound facilitation.Caveats: Open-label with an unblinded events committee, no screening logs, a single homogeneous population, and no one over 80.Tune in to learn where this trial actually moves the needle, and where the enthusiasm outruns the data. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Kroupa J, Radvan M, Mrozek J, et al. Catheter-directed thrombolysis in intermediate-high-risk pulmonary embolism. N Engl J Med. Published online August 31, 2026. doi:10.1056/NEJMoa2608012
The Heparin Paradox: When More is Less
2026/09/09
This episode breaks down a 2026 JVIR letter to the editor describing intraprocedural heparin resistance during iliocaval thrombectomy in a 67-year-old man with stage IV diffuse large B-cell lymphoma and recurrent DVT. The Setup: A chest wall hematoma on therapeutic heparin forced cessation of anticoagulation and IVC filter placement. Two weeks later, thrombus extended from below the filter into the bilateral iliocaval and femoral segments (Villalta 15 to 18, VCSS 12).The Pharmacologic Wall: Despite 13,000 units of heparin (roughly 136 U/kg) targeting an ACT above 250 seconds, values sat at 133 to 138 with thrombus reaccumulating during active aspiration. Day two brought 21,000 units and a unit of FFP, moving the ACT only from 173 to 198.Why It Failed: The 4Ts score was 2, arguing against HIT. Antithrombin III fell from 89% at baseline to 52% post-procedure, pointing to acquired consumption rather than hereditary deficiency.The Algorithm: Confirm dosing, exclude sampling error, then escalate beyond repeat heparin. Options include anti-factor Xa-guided dosing, ATIII concentrate rather than FFP in a volume-overloaded patient, or a direct thrombin inhibitor that does not require ATIII.The Mechanical Half: Filter retrieval and femorotibial venoplasty addressed the thrombogenic nidus and the restricted inflow, since central clearance does not hold without runoff.Caveats: A single case with three problems corrected at once. Neither a direct thrombin inhibitor nor ATIII concentrate was actually given, leaving the recommended pathway untested.Tune in to learn why escalating heparin against a flat ACT wastes table time, and what to reach for instead. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Seo Y, Ahuja T, Chen M, Ranade M. Heparin resistance during iliocaval thrombectomy in a hypercoagulable patient. J Vasc Interv Radiol. 2026. https://doi.org/10.1016/j.jvir.2026.109018
Fractured IVC Filter Fragments: When to Chase the Metal
2026/09/02
This episode breaks down a 5-year Stanford registry of 82 patients presenting with fractured IVC filters and 185 embolized fragments, with commentary from both Dr. Andrew Kesselman, from Stanford Medicine, and Dr. Scott Trerotola, from Penn Medicine. The question is which fragments to chase and which to leave alone. Triage Comes First: Only 87 of 185 fragments (47%) were deemed intravascular and amenable to removal. Retroperitoneal fragments and peripheral pulmonary artery fragments were left alone by protocol, since traction on an extravascular strut risks caval avulsion.Geographic Gradient: Technical success was 100% for caval fragments (65 of 65), 64% in the proximal pulmonary arteries, and 50% for both cardiac and hepatic vein fragments, with an overall rate of 89.7%.The Cardiac Penalty: The one major complication in the series was a cardiac tamponade during right ventricular fragment removal, giving a 12.5% major complication rate for cardiac attempts. With only 8 attempts, the confidence interval runs from 0.3% to 52.7%, so the signal is directional rather than a number to quote in consent.Natural History: Among 19 patients with retained cardiopulmonary fragments, 81% remained asymptomatic at a mean follow-up of 845 days, which supports surveillance for embedded, inaccessible metal.Tools by Zone: Rigid endobronchial forceps dissect through neointimal hyperplasia in the cava, where a snare slips off endothelialized metal. Cardiopulmonary work shifts to snares with a steerable sheath to avoid the subvalvular apparatus.Caveats: Single center with more than 90% outside referrals and over half having failed prior attempts. The headline success rate applies only to the 47% of fragments selected for an attempt, and radiation burden was never quantified.Tune in to learn why the hardest part of fragment retrieval is deciding which pieces to walk away from. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Kesselman AJ, Hoang NS, Sheu AY, Kuo WT. Endovascular removal of fractured inferior vena cava filter fragments: 5-year registry data with prospective outcomes on retained fragments. J Vasc Interv Radiol. 2018;29(6):758-764.
Procedural Path to 91% Complete Pathologic Necrosis
2026/08/26
This episode breaks down COBRAS, a 2026 Radiology multicenter study of 303 patients and 364 treatment-naive HCC tumors bridged to liver transplant with glass microsphere radiation segmentectomy. Listen to the end to hear an expert commentary by Dr. Sid Padia from UCLA Interventional Radiology. Four Parameters: Microsphere activity of at least 1,087 Bq, at least 8,000 microspheres per mL, a single-compartment dose of at least 400 Gy, and an angiosome-to-tumor ratio of 16 or greater.Stacked Result: Positive predictive value for complete pathologic necrosis rose from 74% with activity alone to 91% with all four thresholds met. Meeting none carried a 78% failure rate.Biggest Lever: ATR had the highest odds ratio in the model at 3.4, which argues for pulling the catheter proximal to cover occult parasitic feeders rather than superselecting to the tumor border.Caveats: Retrospective, glass microspheres only, limited to patients who reached transplant, and CPN remains a surrogate endpoint not yet tied to long-term survival.Tune in to learn why the physics inside the vial and the position of your catheter may matter as much as the dose number on the screen. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Berman ZT, De la Garza-Ramos C, Montazeri SA, et al. Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma. Radiology. 2026;319(2):e251923.
Treat the Patient, Not the Picture: Rethinking Pelvic Venous Disease
2026/08/20
This episode breaks down the latest Society of Interventional Radiology guidance on chronic pelvic pain of venous origin, focusing on patient selection and why technically successful procedures may not relieve pain. It concludes with expert commentary from Dr. Gloria Salazar of the UNC School of Medicine. Beyond the Old Labels: The Symptoms-Varices-Pathophysiology classification replaces older labels and distinguishes reflux from obstruction.Pain Is More Than Plumbing: Pelvic floor tension and nervous system sensitization may persist after the venous abnormality is treated.The Supine Imaging Trap: Left renal vein compression changes dramatically with position, making static imaging alone unreliable.Protect the Renal “Pop-Off Valve”: A pressure gradient above 3 mm Hg during ovarian vein occlusion may indicate essential collateral drainage.Technical Pearls: Proper sclerosis, embolic sizing, anchoring, and stent landing zones help prevent treatment failure.Stent or Embolize: Conflicting outcomes show why treatment must target the patient’s dominant pain mechanism.Tune in to learn why pelvic venous interventions should be guided by symptoms and dynamic hemodynamics, not abnormal anatomy alone. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Kaufman CS, Winokur RS, Khilnani NM, et al. The Society of Interventional Radiology Practice Guidance Document on Venous-Origin Chronic Pelvic Pain in Women. J Vasc Interv Radiol. 2026;37:107954.
The Inguinal Ligament Myth: What Really Drives Stent Failure
2026/08/12
This episode pairs a 22-year Stanford retrospective of 1,094 lower extremity venous stents in 406 patients with the 3-year VIVO IDE trial of the Zilver Vena stent, and asks whether crossing the inguinal ligament actually dooms a venous stent. Where the Rule Came From: The recommendation against stenting below the lesser trochanter traces back to citations from 1987 and 1997 that evaluated surgical bypass grafts, not endovascular stents.Apples to Oranges: Mabud reports 57.3% five-year primary patency against VIVO's 90.3% three-year ultrasound patency, but Mabud counts any reintervention as failure. Its five-year assisted patency is also 90.3%.Below the Ligament: Stents extended below the ligament in 32.5% of VIVO patients, with statistically identical 30-day safety (96.2% vs 96.9%, P = .76) and no significant patency difference at 12 months (83.3% vs 93.0%, P = .31). The higher reintervention rate tracked with worse baseline disease: lesions averaged 15.6 cm versus 7.1 cm and were four times more likely to be fully occlusive.Hardware Is Not the Problem: Across roughly 1,459 stents spanning 30 years of technology, including stents landed in the common femoral, femoral, and popliteal veins, there were zero reported fractures.Practical Rule: Normal vein to normal vein, securing at least 8 mm of healthy inflow, downsizing to 10 to 12 mm infra-inguinally. Post-stent, a DOAC alone is sufficient, since adding aspirin increases bleeding without improving patency.Tune in to learn why inflow quality, not an anatomic landmark, should decide where your stent lands. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.Mabud TS, Cohn DM, Arendt VA, et al. Lower extremity venous stent placement: a large retrospective single-center analysis. J Vasc Interv Radiol. 2020;31(2):251-259. Comerota AJ, Gagne P, Brown JA, Segbefia E, Hofmann LV; VIVO Clinical Study Investigators. Final 3-year study outcomes from the evaluation of the Zilver Vena venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction (the VIVO clinical study). J Vasc Interv Radiol. 2024;35(6):834-845.
The TIPS Trade-Off: Bleeding vs. Brain
2026/08/09
This episode tackles the "Goldilocks dilemma" of TIPS: finding the stent diameter that stops a life-threatening variceal bleed without silently destroying a patient's cognition. Listen to the end to hear the expert commentary from Ziv Haskal from University of Virginia. Metabolic Cost: A TIPS decompresses the portal system but shunts ammonia-rich blood past the liver's filter and into the brain, where it triggers the astrocyte swelling behind hepatic encephalopathy (HE).8mm vs. 10mm: The Huang meta-analysis found that 8mm stents delivered better one- and three-year survival and lower HE risk than 10mm stents, despite slightly more shunt dysfunction.6mm vs. 8mm: The Zhang RCT randomized 144 cirrhotic patients to 6mm or 8mm stents. The 6mm group had a higher 2-year rebleeding rate (35.2% vs. 24.1%) but far less overt HE (20.3% vs. 42.0%), with nearly identical survival (84.6% vs. 83.0%).Population Question: The Gong meta-analysis backs this up across mostly Asian cohorts, showing 6–7mm stents roughly halve HE risk versus 8mm without hurting survival. But the data leans on smaller Asian liver volumes and may not translate directly to Western patients.Guideline Shift: EASL now recommends small-diameter stents for patients at high risk of HE, reflecting a shift toward accepting a bit more rebleeding risk to protect the brain.Caveats: The Zhang trial was single-center and open-label, and Gong's conclusions lean on retrospective data that can't fully settle the shunt-dysfunction debate the way Huang's harder data can.Tune in to learn why the field is moving from "bigger is safer" to personalized stent sizing based on individual liver anatomy. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Zhang W, Zhang M, Xiao J, et al. Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2026;24(1):161-171. doi:10.1016/j.cgh.2025.06.023Gong J, Xia Z, Zhou Z, Chen L, Wang X, Zhou F. Effectiveness and prognosis of covered stents with different diameters in transjugular intrahepatic portosystemic shunt: a meta-analysis. Eur J Gastroenterol Hepatol. 2024;36(2):229-237. doi:10.1097/MEG.0000000000002696Huang Z, Yao Q, Zhu J, He Y, Chen Y, Wu F, Hua T. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) created using covered stents of different diameters: A systematic review and meta-analysis. Diagn Interv Imaging. 2021;102(5):279-285. doi:10.1016/j.diii.2020.11.004
From CTA to the Angio Suite: A GI Bleeding Playbook
2026/08/05
This episode breaks down the 2024 ACG/Society of Abdominal Radiology consensus statement alongside a 2025 Duke University update, mapping out exactly which imaging test to reach for at each stage of a GI bleed and when IR should step in.  Dr. Rusty Hofmann from Stanford University closes with his commentary. CTA Takes First-Line: For unstable patients or high clinical suspicion, CTA now leads with ~95% accuracy, and even a negative scan is useful, it predicts lower rebleeding and reintervention rates.The RBC Scan's Blind Spot: Reserved for stable, post-negative-colonoscopy cases, tagged RBC scans carry a 10-33% localization error, enough to send an IR team down the wrong vessel entirely.CTE Over Capsule for Small Bowel: CT enterography is now preferred first-line for small bowel bleeding, especially with capsule-retention risk or suspected GISTs that a pill camera would miss.Coils Beat Particles: At the vasa recta, particle embolization carried 5.3% severe ischemia risk versus 0% for coils alone, a strong case for targeted, extravasation-confirmed embolization.The Break-Glass Option: When all standard imaging fails, provocative mesenteric angiography proved safe via first-pass hepatic clearance of TPA, but only pays off with hematochezia plus a prior positive study; melena with clean imaging predicts a wasted procedure.Tune in to build a modality-by-modality protocol, from first scan to break-glass angiogram. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.ACG and SAR Consensus Statement on GI Bleeding Imaging: Sengupta N, Kastenberg DM, Bruining DH, et al. The Role of Imaging for GI Bleeding: ACG and SAR Consensus Recommendations. Radiology. 2024;310(3):e232298Duke University Provocative Angiography Study: Benvenuti et al. Provocative Mesenteric Angiography for Obscure Gastrointestinal Hemorrhage: An Update on Outcomes, Safety, and Predictors of Success. J Vasc Interv Radiol. 2025;36:1558-1566

Podcast reviews

Read Wysdom Radio™ podcast reviews


5 out of 5
2 reviews

Podcast sponsorship advertising

Start advertising on Wysdom Radio™ relevant audience podcasts


What do you want to promote?